Cancer Markers (Male)

Comprehensive Cancer Screening at Home

Vesta Care's Cancer Markers Male package delivers targeted screening for the most common cancers affecting men, measuring seven specialized tumor markers alongside complete blood analysis. This comprehensive 27-biomarker assessment detects early warning signs of prostate, colorectal, pancreatic, liver, and testicular cancers—cancers accounting for the majority of male cancer diagnoses and deaths.

At AED 479, this screening provides essential cancer surveillance through blood and stool testing performed conveniently at your Dubai home. Our DHA-licensed phlebotomists collect samples throughout Dubai—from Business Bay to Arabian Ranches, JBR to Silicon Oasis—with results delivered in 48 hours. No fasting required, making scheduling maximally convenient.

Understanding Cancer Markers

Cancer markers, also called tumor markers, are substances produced by cancer cells or by the body in response to cancer. These markers serve as important tools in diagnosing, staging, and monitoring treatment of many cancers, with serum-based markers most commonly used due to relative ease and lower testing cost. While not definitive for diagnosis alone, elevated markers indicate increased cancer risk requiring further investigation.

This screening isn't mass population testing—it's targeted surveillance for men with risk factors: family cancer history, age over 40, unexplained symptoms, previous abnormal tests, lifestyle risks like smoking, or those seeking proactive health monitoring. Early detection through marker screening enables intervention when treatment success rates are highest.

The 7 Specialized Cancer Markers

Prostate-Specific Antigen (PSA) Total – The primary prostate cancer screening marker. Elevated PSA levels indicate increased prostate cancer risk, though elevation can also result from benign prostatic hyperplasia or prostatitis. Total PSA provides the baseline measurement for prostate health assessment.

PSA Free – Measures the unbound PSA circulating in blood. The free PSA to total PSA ratio helps distinguish between benign conditions and cancer—lower ratios suggesting higher cancer probability. This ratio improves specificity beyond total PSA alone.

Carcinoembryonic Antigen (CEA) – A tumor marker often elevated in colorectal, pancreatic, stomach, liver, thyroid, breast, and prostate cancers. CEA serves as both a screening tool and treatment monitoring marker, with levels typically normalizing after successful cancer treatment.

CA 19-9 (Cancer Antigen 19-9) – A protein most often associated with pancreatic cancer, also sometimes elevated in gallbladder, colorectal, ovarian, lung, and liver cancers. Pancreatic cancer, often diagnosed late, benefits significantly from early marker detection enabling timelier intervention.

Alpha-Fetoprotein (AFP) – A tumor marker sometimes elevated in liver, ovarian, and testicular cancers. AFP is particularly valuable for hepatocellular carcinoma (liver cancer) screening, especially in men with hepatitis B, hepatitis C, or cirrhosis—conditions increasing liver cancer risk substantially.

Stool Occult Blood – Detects hidden blood in stool invisible to the naked eye. Positive results indicate gastrointestinal bleeding potentially caused by colorectal cancer, polyps, inflammatory bowel disease, or other conditions requiring colonoscopy evaluation.

Complete Blood Count (21 parameters) – Comprehensive blood cell analysis detecting abnormalities potentially indicating blood cancers, chronic disease effects, or cancer-related anemia. Changes in white blood cells, red blood cells, or platelets can signal underlying malignancy requiring investigation.

Check here: Cancer Markers (Female)

Why Combined Marker Testing?

Single markers have limitations—cancers don't always elevate their "typical" marker, and benign conditions can cause elevations. Combined testing increases detection sensitivity substantially. Research demonstrates that multiple marker combinations improve cancer detection rates significantly compared to single markers.

For instance, someone with early colorectal cancer might show elevated CEA and positive stool occult blood together, providing stronger evidence than either test alone. Similarly, liver cancer surveillance benefits from combined AFP and CEA measurement, while prostate assessment improves through analyzing both total and free PSA together.

Critical Limitations to Understand

Cancer markers are screening tools, not diagnostic tests. Important facts:

• Elevated markers don't confirm cancer – Many benign conditions cause elevations
• Normal markers don't rule out cancer – Early cancers may not elevate markers
• Further testing required – Abnormal results demand imaging, biopsies, or colonoscopy
• False positives occur – Causing anxiety but preventing delayed diagnosis when needed
• Medical interpretation essential – Results require physician evaluation in clinical context

This screening identifies men requiring additional investigation—it doesn't diagnose cancer. However, early marker detection enables intervention when curative treatment remains possible, potentially lifesaving for those with occult malignancies.

Who Should Get Cancer Marker Screening?

This assessment particularly benefits men with:

• Age over 40-45 when cancer incidence increases
• Family cancer history multiplying personal risk substantially
• Chronic liver disease (hepatitis B/C, cirrhosis) increasing liver cancer risk
• Smoking history elevating multiple cancer risks
• Unexplained symptoms (weight loss, fatigue, abdominal pain, blood in stool)
• Previous polyps requiring colorectal surveillance
• Prostate symptoms (urinary frequency, weak stream, nocturia)
• High-risk occupations with carcinogen exposure

Simple At-Home Sample Collection

No fasting required for this test, making scheduling convenient around your routine. Our certified phlebotomists arrive at your Dubai location—home, office, or hotel—at your preferred time. Blood collection takes minutes, with stool collection instructions provided for home completion.

Samples are transported immediately to our CAP-accredited laboratory where specialized immunoassay analyzers measure each tumor marker with precision. Results arrive electronically within 48 hours, reviewed by our Clinical Pathologists who flag elevated markers requiring medical attention.

Complimentary Medical Consultation Included

Every Cancer Markers Male test includes physician consultation following result delivery. Our DHA-licensed doctors explain findings, interpret elevations in clinical context, recommend additional testing when warranted, arrange specialist referrals for concerning results, and provide reassurance when markers are normal.

If markers are elevated, we guide you through next steps—whether that's repeat testing, imaging studies, specialist consultation, or continued monitoring—ensuring concerning findings receive appropriate follow-up rather than causing unnecessary anxiety or being ignored dangerously.

Proactive Cancer Surveillance

At AED 479, this comprehensive screening delivers peace of mind for those with normal results and potentially lifesaving early detection for those with occult malignancies. Cancer detected early through marker screening offers dramatically better treatment outcomes and survival rates than cancer diagnosed after symptoms develop.

This isn't about creating health anxiety—it's about intelligent surveillance enabling intervention when treatment works best. Men with risk factors benefit substantially from periodic marker monitoring, establishing baselines and detecting changes requiring investigation.

Book Your Cancer Screening Today

Schedule your Cancer Markers Male test through Vesta Care at +971 52 270 4729. Our service operates throughout Dubai with same-day appointments, professional home collection, 48-hour results, specialist pathologist review, and complimentary medical consultation. Payment accepts cash, credit cards, and Tabby installments.

Take control of your cancer risk through proactive screening. Early detection saves lives—book your comprehensive male cancer marker assessment now.